Under clinical condition there is sufficient evidence supporting the presence of a graft-vs-leukemia (GVL) effect after allogeneic stem cell transplantation (SCT). Such conditions include a reduced risk of relapse in patients developing GVHD, an increased risk of relapse after syngeneic transplants, and, most convincing, the reinduction of a CR after relapse from allogeneic SCT byby infusing donor lymphocytes. Based on the fact that blood stem cell allografts contain ten times more lymphoid cells and four times more CD §$+ cells as compared with bone marrow allografts, apotentially more pronounced GVL effect could be achieved. With this being a primary therapeutic goal, non-myeloablative transplant regimens have been designed to provide, in addition to a direct antitumour effect, sufficient immunosuppression to prevent graft rejection and achieve temporary or sustained engraftment of immunocompetent donor cells directed against allogeneic target antigens. This less toxic treatment strategy 1) is primarily aimed at patients who are ineligible for high-dose myeloablative treatment because of age and/or comorbidities, 2) is presumably followed by less severe acute GVHD, and 3) allows in case of nonengraftment autochthonous hematopoietic reconstitution without risk of permanent engraftment failure.
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As shown by us, purin analog (claribine or fludarabine) containing transplant regimens provide sufficient immunosuppression to allow permanent engraftment of HLA matched stem cells in patients with AML, CML, CLL, multiple myeloma and low grade lymphoma. In patients with refractory or recurrent CLL or lymphoma, 11/15 patients showed evidence of engraftment (50 to 100% donor cells at one month post-transplant) when using fludarabine/ cyclophosphamide or fludarabine, cytarabine, cisplatin. All 11 engrafted patients have responded (8/11 achieved CR).
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The therapeutic efficiency of non-ablative transplant regimens has been proven but depends on the patient's disease status (CR or refractory relapse), on the immunocompetence of the recipient and on the intensity of the posttransplant immunosuppressive treatment. Adoptive immunotherapy using donor lymphocyte transfusions (DLT) is a highly effective treatment of relapsed chronic myelocytic leukemia (CML) or multiple myeloma (MM) following allogeneic hematopoietic stem cell transplantation (HSCT). In 36 patients the rate of complete remission was 72% but was associated with severe graftversus-host-disease (GvHD) in 67% of the patients and a high mortality rate of 14%. In order to reduce the incidence and severity of GvHD and the DLT related mortality while preserving the anti-tumor effect 10 patients with relapse of CML (n = 5) or persistent MM (n = 5) received 1 × 10 7 CD4 + cells per kg body weight after allogeneic HSCT. Methods: A median of 0.7 (0.4-1.1) × 10 10 leukocytes with about 40% CD4 + and 20% CD8 + cells was collected from the original stem cell donor using the COBE Spectra™ cell separator. The apheresis products were washed and incubated with anti-CD8 labeled immunomagnetic beads (Baxter, Germany). Phenotyping after magnetic separation showed a high depletion efficiency of 3.3 (2.8-3.4) log for CD8 + cells and a sufficient recovery of 73 (60-99)% for CD4 + cells reaching the target cell dose of 1 × 10 7 CD4 + cells per kg b.w. of the recipient. Results: 3 out of the 5 patients with relapsed CML are in molecular remission 4-9 months after CD4 + cell transfusion. 1 patient is too early for evaluation and 1 patient died of pneumonia. In all 5 patients with MM PCR became negative or the paraprotein disappeared indicating a response and anti-tumor effect of CD8-depleted DLT. Four patients developed only mild acute or a primary chronic GvHD of the skin. Bone marrow aplasia occurred in none patient. Conclusion: CD8-depleted DLT can be prepared by a single immunomagnetic separation step of apheresis products and are effective in treating relapsed CML or MM after allogeneic HSCT. Because of the reduced risk of GvHD and mortality associated with DLT, prophylactic transfusions can be given in patients with high risk of relapse after allogeneic transplantation. Although preliminary data demonstrated that induction of mixed chimerism (MC) is possible using minimal conditioning regimen, little is known about the development of chimerism of different compartments after non-myeloablative conditioning regimen. Patients and methods: Chimerism status was analyzed in seven patients who received an allogeneic PBSCT after conditioning with 2 Gy TBI only as previously published by Storb et al. (BLOOD 89: 3048, 1997) . Two patients with AML in 2 nd CR and 1 st PR, four with CML (2 chronic phase, 2 accelerated phase), one with ALL in 3 rd relapse received PBSCT from HLA-identical siblings (6) or from a HLA-matched unrelated donor (n = 1). Chimerims status was repeatedly analyzed for myeloid, T-and NK-cells of the peripheral blood and bone marrow aspirate sorted by S5 FACS. Analysis of chimerism were performed using quantitative analysis of fluorescence labeled PCR-products of short tandem repeat loci and if appropriate by FISH for sex chromosomal differences. Results: Complete chimerism (CC) was induced in two patients (1 ALL 3 rd PR, AML 1 st PR) without additional DLI. CC was reached at day 42 and day 64 post PBSCT. Both patients are in complete remission. MC was induced in the remaining four patients with one being in complete remission from her CML. Significant MC was detected as early as day 3 post PBSCT in the peripheral blood. On day 13 donor myeloid cells ranged from 7% up to 90%, donor T-cells ranged from 14% up to 60% and NK cells ranged from 7% up to 100% donor cells. Overall development of chimerism of granulocytes and NK-cells preceded the Tcell chimerism. Three patients developed acute GVHD which responded to Cyclosporine A and Steroids. While one of them developed CC, two remained with a mixed Tcell chimerism despite acute GVHD.
S2d: Induction of Mixed Chimerism in Patients with
We conclude that induction of CC or MC is feasible in high risk patients using related or unrelated PBSC donors with 2Gy TBI only sparing severe toxicity from myeloablative conditioning regimen. Furthermore the results demonstrate that development of acute GVHD may occur despite mixed T-cell chimerism and is not necessarily associated with development of complete chimerism.
